Definition:
Galinpepimut-S (WT1) is a cancer immunotherapy vaccine designed to stimulate the immune system to target and destroy cells expressing the WT1 (Wilms Tumor 1) protein, which is commonly overexpressed in various cancers, including mesothelioma.
Phonetic Pronunciation:
(GAH-lin-pep-ih-moot-ESS)
Etymological Origin:
The term "Galinpepimut-S" is derived from its scientific components: "Galin" refers to its peptide-based nature, "pepimut" indicates its role as a peptide immunotherapy, and "S" denotes a specific formulation. WT1 refers to the Wilms Tumor 1 protein, named after Max Wilms, a German surgeon who first described Wilms' tumor, a type of kidney cancer.
Significance in Asbestos Context:
Galinpepimut-S is significant in the asbestos context because it is being studied as a treatment for mesothelioma, a cancer strongly linked to asbestos exposure. Mesothelioma often overexpresses the WT1 protein, making it a target for this vaccine. By enhancing the immune system's ability to recognize and attack WT1-expressing cells, Galinpepimut-S offers a potential therapeutic option for patients with asbestos-related mesothelioma.
Synonyms or Related Terms:
Example Sentence:
"Clinical trials of Galinpepimut-S have shown promise in improving survival rates for mesothelioma patients, a cancer caused by prolonged asbestos exposure."
Common Misconceptions:
